All In Biotech

NDA 213051 · Novo

Ozempic

Semaglutide · Oral · GLP-1 Receptor Agonist

Priority review

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Sep 20, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

626

187 Phase 3, 161 recruiting

FAERS reports

78,023

39,105 serious, 1,364 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether RYBELSUS and OZEMPIC tablets cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), Nonclinical Toxicology ( 13.1 )] . • RYBELSUS and OZEMPIC tablets are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent...

What it is approved for

From the label in effect Jan 30, 2026.

RYBELSUS and OZEMPIC tablets are indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 (GLP-1) receptor agonists indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )

Mechanism: Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide...

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • OZEMPIC · SEMAGLUTIDE 9MG · TABLET, ORAL · Prescription
  • OZEMPIC · SEMAGLUTIDE 1.5MG · TABLET, ORAL · Prescription
  • RYBELSUS · SEMAGLUTIDE 7MG · TABLET, ORAL · Prescription
  • OZEMPIC · SEMAGLUTIDE 4MG · TABLET, ORAL · Prescription
  • RYBELSUS · SEMAGLUTIDE 14MG · TABLET, ORAL · Prescription
  • RYBELSUS · SEMAGLUTIDE 3MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Semaglutide" as an intervention, any sponsor and status, largest first.

All 626 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea11,150
  • off label use7,890
  • vomiting7,332
  • diarrhoea6,833
  • decreased appetite5,107
  • constipation4,976
  • weight decreased4,777
  • impaired gastric emptying4,175
  • product use in unapproved indication3,761
  • blood glucose increased3,460
  • fatigue3,252
  • headache3,240

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20132
20143
20157
201614
201714
20181,142
20191,596
20203,514
20214,563
20226,320
20239,506
202414,313
202520,019
202617,010

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jun 4, 2026

    Rybelsus, Tablet, 3 mg (NDC 0169-4303-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

  • To Be Discontinued · updated Jun 4, 2026

    Rybelsus, Tablet, 7 mg (NDC 0169-4307-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

  • To Be Discontinued · updated Jun 4, 2026

    Rybelsus, Tablet, 14 mg (NDC 0169-4314-30). Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ozempic (Semaglutide)

2024 spending

$13.0B

Beneficiaries

1,952,637

10,417,182 claims

Per beneficiary

$6,642

$306.48 per unit

View as table
YearSpending
2020$1,455,812,267
2021$2,621,694,348
2022$4,628,160,643
2023$9,194,048,435
2024$12,970,296,347

Part D: Rybelsus (Semaglutide)

2024 spending

$1.89B

Beneficiaries

309,993

1,251,733 claims

Per beneficiary

$6,097

$30.59 per unit

View as table
YearSpending
2020$73,444,409
2021$454,563,823
2022$974,894,470
2023$1,665,906,943
2024$1,890,082,026

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 784 on PubMed

Sponsor: Novo · Also marketed as Rybelsus

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.